Coote Susan, Uszynski Marcin, Herring Matthew P, Hayes Sara, Scarrott Carl, Newell John, Gallagher Stephen, Larkin Aidan, Motl Robert W
Department of Clinical Therapies, University of Limerick, Limerick, Ireland.
Health Research Institute, University of Limerick, Limerick, Ireland.
BMC Neurol. 2017 Jun 24;17(1):119. doi: 10.1186/s12883-017-0898-y.
Recent exercise guidelines for people with multiple sclerosis (MS) recommend a minimum of 30 min moderate intensity aerobic exercise and resistance exercise twice per week. This trial compared the secondary outcomes of a combined 10-week guideline based intervention and a Social Cognitive Theory (SCT) education programme with the same exercise intervention involving an attention control education.
Physically inactive people with MS, scoring 0-3 on Patient Determined Disease Steps Scale, with no MS relapse or change in MS medication, were randomised to 10-week exercise plus SCT education or exercise plus attention control education conditions. Outcomes included fatigue, depression, anxiety, strength, physical activity, SCT constructs and impact of MS and were measured by a blinded assessor pre and post-intervention and 3 and 6 month follow up.
One hundred and seventy-four expressed interest, 92 were eligible and 65 enrolled. Using linear mixed effects models, the differences between groups on all secondary measures post-intervention and at follow-up were not significant. Post-hoc, exploratory, within group analysis identified improvements in both groups post intervention in fatigue (mean ∆(95% CI) SCT -4.99(-9.87, -0.21), p = 0.04, Control -7.68(-12.13, -3.23), p = 0.00), strength (SCT -1.51(-2.41, -0.60), p < 0.01, Control -1.55(-2.30, -0.79), p < 0.01), physical activity (SCT 9.85(5.45, 14.23), p < 0.01, Control 12.92(4.69, 20.89), goal setting (SCT 7.30(4.19, 10.4), p < 0.01, Control 5.96(2.92, 9.01), p < 0.01) and exercise planning (SCT 5.88(3.37, 8.39), p < 0.01, Control 3.76(1.27, 6.25), p < 0.01) that were maintained above baseline at 3 and 6 month follow up (all p < 0.05). Only the SCT group improved at 3 and 6 month follow up in physical impact of MS(-4.45(-8.68, -0.22), -4.12(-8.25, 0.01), anxiety(-1.76(-3.20, -0.31), -1.99(-3.28, -0.71), depression(-1.51(-2.89, -0.13), -1.02(-2.05, 0.01)) and cognition(5.04(2.51, 7.57), 3.05(0.81, 5.28), with a medium effect for cognition and fitness (Hedges' g 0.75(0.24, 1.25), 0.51(0.01, 1.00) at 3 month follow up.
There were no statistically significant differences between groups for the secondary outcomes once age, gender, time since diagnosis and type of MS were accounted for. However, within the SCT group only there were improvements in anxiety, depression, cognition and physical impact of MS. Exercising at the minimum guideline amount has a positive effect on fatigue, strength and PA that is sustained at 3 and 6 months following the cessation of the program.
ClinicalTrials.gov, NCT02301442 , retrospectively registered on November 13th 2014.
近期针对多发性硬化症(MS)患者的运动指南建议,每周至少进行两次30分钟的中等强度有氧运动和阻力运动。本试验比较了基于指南的为期10周的综合干预与社会认知理论(SCT)教育计划的次要结果,二者均采用相同的运动干预,并设有注意力控制教育对照。
身体活动不足的MS患者,在患者确定疾病阶段量表上得分为0 - 3分,且无MS复发或MS药物治疗变化,被随机分配至为期10周的运动加SCT教育组或运动加注意力控制教育组。结局指标包括疲劳、抑郁、焦虑、力量、身体活动、SCT结构以及MS的影响,由一名盲法评估者在干预前后以及干预后3个月和6个月随访时进行测量。
174人表示感兴趣,92人符合条件,65人入组。使用线性混合效应模型,干预后及随访时两组在所有次要测量指标上的差异均无统计学意义。事后探索性组内分析发现,两组干预后在疲劳(平均变化量(95%置信区间)SCT组 -4.99(-9.87,-0.21),p = 0.04,对照组 -7.68(-12.13,-3.23),p = 0.00)、力量(SCT组 -1.51(-2.41,-0.60),p < 0.01,对照组 -1.55(-2.30,-0.79),p < 0.01)、身体活动(SCT组9.85(5.45,14.23),p < 0.01,对照组12.92(4.69,20.89))、目标设定(SCT组7.30(4.19,10.4),p < 0.01,对照组5.96(2.92,9.01),p < 0.01)和运动计划(SCT组5.88(3.37,8.39),p < 0.01,对照组3.76(1.27,6.25),p < 0.01)方面均有改善,且在3个月和6个月随访时均维持在基线以上(所有p < 0.05)。仅SCT组在3个月和6个月随访时,MS的身体影响(-4.45(-8.68,-0.22),-4.12(-8.25,0.01))、焦虑(-1.76(-3.20,-0.31),-1.99(-3.28,-0.71))、抑郁(-1.51(-2.89,-0.13),-1.02(-2.05,0.01))和认知(5.04(2.51,7.57),3.05(0.81,5.28))方面有所改善,认知和健康方面有中等效应大小(3个月随访时Hedges' g 0.75(0.24,1.25),0.故51(0.01,1.00))。
在考虑年龄、性别、诊断后时间和MS类型后,两组次要结局指标无统计学显著差异。然而,仅在SCT组中,焦虑、抑郁、认知和MS的身体影响有所改善。按照最低指南量进行运动对疲劳、力量和身体活动有积极影响,且在运动计划停止后的3个月和6个月仍持续存在。
ClinicalTrials.gov,NCT02301442,于2014年11月13日进行回顾性注册。